Atara Biotherapeutics Inc ATRA

THOUSAND OAKS, Calif., September 30, 2026--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today provided an update that its partner, Pierre Fabre Pharmaceuticals, Inc. (PFP), has resubmitted the tabelecleucel Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA).

THOUSAND OAKS, Calif., August 12, 2026--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the second quarter 2026 and business updates.

Biotech stocks climbed Wednesday after the Food and Drug Administration signaled the end of a "nail-biting journey" for UniQure.

THOUSAND OAKS, Calif., June 12, 2026--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the departure of Carol Gallagher, Pharm D from its Board of Directors.

Atara Biotherapeutics said the FDA outlined a potential pathway for resubmitting the tabelecleucel application after a recent Complete Response Letter. Key Investor TakeawaysAtara Biotherapeutics (NASDAQ:ATRA) said the FDA discussed a potential resubmission path for tabelecleucel following a Type A meeting.

We recently compiled a list of the 10 Best Cheap Stocks Under $10 to Buy in April. Atara Biotherapeutics, Inc. is among the best cheap stocks to buy. TheFly reported on March 17 that ATRA filed a prospectus to register the potential resale of up to 400,000 common shares by HCR Molag Fund, L.P. These […]